A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome

Journal of Developmental and Behavioral Pediatrics

Volumn 34, Issue 3, 2013, Pages 147-155

  Leigh, Mary Jacena S ^a,b   Nguyen, Danh V ^c   Mu, Yi ^c   Winarni, Tri I ^d   Schneider, Andrea ^a,b   Chechi, Tasleem ^a,b   Polussa, Jonathan ^a,b   Doucet, Paul ^b   Tassone, Flora ^b,e   Rivera, Susan M ^b,c   Hessl, David ^b,c   Hagerman, Randi J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DIPONEGORO UNIVERSITY   (Indonesia)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

fragile X syndrome; intellectual disability; matrix metalloproteinase 9; minocycline

Indexed keywords

MINOCYCLINE; NEUROPROTECTIVE AGENT;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FRAGILE X SYNDROME; HUMAN; INTELLIGENCE; MALE; PRESCHOOL CHILD; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FRAGILE X SYNDROME; HUMANS; INTELLIGENCE; MALE; MINOCYCLINE; NEUROPROTECTIVE AGENTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOLOGICAL TESTS; TREATMENT OUTCOME;

EID: 84876358587     PISSN: 0196206X     EISSN: 15367312     Source Type: Journal    
DOI: 10.1097/DBP.0b013e318287cd17     Document Type: Article

References (37)

1. Crawford DC, Meadows KL, Newman JL, et al. Prevalence of the fragile X syndrome in African-Americans. Am J Med Genet. 2002; 110:226-233
2. Hagerman PJ. The fragile X prevalence paradox. J Med Genet. 2008; 45:498-499
3. Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Postadolescent changes in regional cerebral protein synthesis: An in vivo study in the FMR1 null mouse. J Neurosci. 2005;25:5087-5095
4. Darnell JC, Van Driesche SJ, Zhang C, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146:247-261
5. De Rubeis S, Bagni C. Fragile X mental retardation protein control of neuronal mRNA metabolism: Insights into mRNA stability. Mol Cell Neurosci. 2010;43:43-50
6. Hoeffer CA, Sanchez E, Hagerman RJ, et al. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav. 2012;11:332-341
7. Dolen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile X. Pharmacol Ther. 2010;127:78-93
8. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ. 2012;54: 297-335
9. Berry-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46:266-271
10. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3: 64ra1
11. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29:293-302
12. Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci Transl Med. 2012;4:152ra127
13. Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009;46:94-102
14. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516
15. Michaluk P, Wawrzyniak M, Alot P, et al. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci. 2011;124:3369-3380
16. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A. 1999;96:13496-13500
17. Siller SS, Broadie K. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech. 2011;4:673-685
18. Rotschafer SE, Trujillo MS, Dansie LE, Ethell IM, Razak KA. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of fragile X syndrome. Brain Res. 2012;1439:7-14
19. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol. 2010;67:1442-1448
20. Smith K, Leyden JJ. Safety of doxycycline and minocycline: A systematic review. Clin Ther. 2005;27:1329-1342
21. Utari A, Chonchaiya W, Rivera SM, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil. 2010;115:433-443
22. Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010;10:91
23. Roid GH. Stanford Binet Intelligence Scales. 5th ed. Rolling Meadows, IL: Riverside Publishing Co.; 2003
24. Wechsler D. Wechsler Abbreviated Scale of Intelligence (WASI). San Antonio, TX: Harcourt Assessment, Inc.; 1999
25. Mullen EM. Mullen Scales of Early Learning. Circle Pines, MN: American Guidance Service; 1995
26. Flemmer DD, Roid GH. Nonverbal intellectual assessment of Hispanic and speech-impaired adolescents. Psychol Rep. 1997;80: 1115-1122
27. Facco E, Zanette G, Favero L, et al. Toward the validation of visual analogue scale for anxiety. Anesth Prog. 2011;58:8-13
28. de Boer AG, van Lanschot JJ, Stalmeier PF, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res. 2004;13:311-320
29. Di Benedetto M, Lindner H, Hare DL, Kent S. A Cardiac Depression Visual Analogue Scale for the brief and rapid assessment of depression following acute coronary syndromes. J Psychosom Res. 2005;59:223-229
30. Aman MG, Burrow WH, Wolford PL. The Aberrant Behavior Checklist-Community: Factor validity and effect of subject variables for adults in group homes. Am J Ment Retard. 1995;100:283-292
31. Sansone SM, Widaman KF, Hall SS, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord. 2012; 42:1377-1392
32. Williams KT. Expressive Vocabulary Test. Circle Pines, MN: American Guidance Service; 1997
33. Sparrow SS, Cicchetti DV, Balla DA. Vineland Adaptive Behavior Scales. 2nd ed. Circle Pines, MN: American Guidance Service; 2005
34. Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008;10:43-49
35. Bonelli RM, Heuberger C, Reisecker F. Minocycline for Huntington's disease: An open label study. Neurology. 2003;60: 883-884
36. Metz LM, Li D, Traboulsee A, et al. Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: Results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler. 2009;15:1183-1194
37. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist. 2005;11:308-322